BioSpace News Archive

CooperCompanies, announced it will release first quarter 2021 financial results on Thursday, March 4, 2021, at 4:15 PM ET.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the start of the rolling review process for authorization of NVX-CoV2373, its COVID-19 vaccine, by multiple regulatory agencies.

Reported sales increased 11% compared with the prior year. In local currency, sales increased 7% in the quarter as currency benefited reported sales growth by 4%.

- Medicure Inc.(TSXV:MPH) (OTC:MCUJF), announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 8, 2021 at 2:00 PM EST ( 1:00 PM CST , 12:00 PM MST ).

The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Feb. 26, 2021, to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Janssen Biotech Inc.

Newly updated dental and oral healthcare services have been launched by Westlake Dental Arts. These include quality porcelain veneers to improve the appearance of smiles.

European investors have also provided written indication of strong interest for the potential of additional €25 million in similar convertible bonds, depending on future market conditions

Lucira Health, Inc., a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, announced the pricing of its upsized initial public offering of 9,000,000 shares of common stock at a price to the public of $17.00 per share.

Nayya, an AI-driven software platform that provides benefits decision support and engagement, is pleased to announce its partnership with Selerix, a leading provider of cloud-based benefits administration software. Nayya is now fully embedded and integrated within the Selerix BenSelect platform

Petros Pharmaceuticals, Inc. (Petros or the Company) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today announced that it has formed a steering committee to develop expanded patient access initiatives, including non-prescription or Over the Counter (OTC) status strategies, for its STENDRA®